<- Go Home
LianMedical
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was formerly known as LianBio and changed its name to LianMedical in July 2026. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Market Cap
$5.2M
Volume
209.1K
Cash and Equivalents
$103.5M
EBITDA
-$105.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$0.18
52 Week Low
$0.04
Dividend
N/A
Price / Book Value
0.03
Price / Earnings
-0.06
Price / Tangible Book Value
0.03
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$106.6M
Return on Equity
32.42%
Return on Assets
-21.67
Cash and Short Term Investments
$252.2M
Debt
$2.8M
Equity
$236.1M
Revenue
N/A
Unlevered FCF
-$36.9M
Sector
Biotechnology
Category
N/A